PI3KγD946GST Human

Phosphoinositide 3-kinases (PI3Ks) are a family of enzymes involved in various cellular functions, including cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking . These enzymes play a crucial role in signal transduction pathways by phosphorylating the 3’ position hydroxyl group of the inositol ring of phosphatidylinositol . Among the different isoforms of PI3Ks, the p110γ isoform is of particular interest due to its unique regulatory mechanisms and involvement in immune cell function .

The p110γ isoform is part of the class IB PI3Ks and is activated by G protein-coupled receptors (GPCRs) . It forms a heterodimer with either p101 or p84/p87 regulatory subunits, which are unrelated to the p85 regulatory subunits found in class IA PI3Ks . The p110γ isoform is predominantly expressed in leukocytes and plays a significant role in immune responses, particularly in the regulation of mast cell degranulation and eosinophilic inflammation .

The inactive mutant of p110γ is a recombinant form of the enzyme that has been genetically modified to lack catalytic activity. This modification allows researchers to study the non-catalytic roles of p110γ in cellular processes and to investigate the effects of its inhibition on various signaling pathways. The inactive mutant serves as a valuable tool in understanding the specific contributions of p110γ to immune cell function and its potential as a therapeutic target for inflammatory diseases and cancer .

The p110γ isoform has been implicated in the development of eosinophilic inflammation, making it a potential therapeutic target for treating eosinophil-related diseases such as asthma . Additionally, the role of p110γ in immune cell function and its involvement in cancer signaling pathways highlight its importance in therapeutic development. Inhibitors targeting p110γ are being explored for their potential to modulate immune responses and to serve as treatments for cancer and inflammatory diseases .